Halozyme Therapeutics Inc (HALO) — Cash Flow Reinvestment Rate
Halozyme Therapeutics Inc (HALO) has a Cash Flow Reinvestment Rate of 1.15x as of September 2025, reinvesting $204.64 Million (capex $3.03 Million plus investments $201.61 Million) from operating cash flow of $178.60 Million. Check HALO operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Halozyme Therapeutics Inc Cash Flow Reinvestment Rate (2006–2024)
Historical reinvestment intensity for Halozyme Therapeutics Inc across 7 annual periods. Explore cash flow to debt ratio of Halozyme Therapeutics Inc to assess how comfortably operating cash covers total debt obligations.
Annual Cash Flow Reinvestment Rate for Halozyme Therapeutics Inc (2006–2024)
Year-by-year capital reinvestment analysis for Halozyme Therapeutics Inc. For live market cap and broader valuation context, see HALO market cap.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.57x | $273.42 Million | $479.06 Million | $10.70 Million | ▲ +97.7% |
| 2023 | 0.29x | $112.20 Million | $388.57 Million | $15.29 Million | ▼ -86.0% |
| 2022 | 2.06x | $495.73 Million | $240.11 Million | $4.81 Million | ▲ +52.2% |
| 2021 | 1.36x | $406.29 Million | $299.44 Million | $1.46 Million | ▼ -8.6% |
| 2020 | 1.48x | $82.29 Million | $55.45 Million | $2.50 Million | ▲ +20.5% |
| 2017 | 1.23x | $165.08 Million | $134.05 Million | $1.35 Million | ▲ +2289.9% |
| 2006 | 0.05x | $364.80K | $7.08 Million | $364.80K | — |